CoChat

Diabetes, Impaired Fasting Glucose, and Heart Failure: Its not All About the Sugar

Open access
Sharma, Abhinav, Ezekowitz, Justin A. · 2014 · European Journal of Heart Failure
Cited by 22

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

The linkage between diabetes and the development of cardiovascular disease is well established, including the development of a distinct diabetic cardiomyopathy, the co-existence of coronary artery disease (CAD) and the high prevalence (up to 40%) of diabetes in patients presenting with acute heart failure (AHF).1 Patients with diabetes are at higher risk of developing heart failure (HF)2 and, once present, it is associated with poor clinical outcomes.1 However, the adequacy of glycaemic control for patients with both diabetes and HF remains controversial with no clear association of glycated haemoglobin (HbA1c) and clinical events.3 Abnormalities in glucose regulation in patients without diabetes, such as impaired fasting glucose (IFG), abnormal oral glucose tolerance, or an elevated HBA1c, is present in up to 23% of HF patients.4 Furthermore, IFG is associated with worse outcomes in the setting of acute HF.4 Thus, there are three major questions that need addressing when dissecting issues relating to glucose regulation in patients with HF: (i) Is diabetes independent and directly driving the complications seen in patients with HF, or are the associated co-morbidities (CAD, hypertension, and renal disease) the driving force?; (ii) Why do patients with concomitant diabetes and HF do worse than patients without diabetes?; (iii) Can any diabetes-related therapy modify the outcomes for patients with HF? At a population level, the presence of diabetes increases the adjusted relative risk of the development of HF in men and women by 1.82 and 3.75, respectively.2 Despite these associations, there are conflicting results regarding the prognostic value of diabetes in patients with established HF. In both acute and chronic HF risk prediction models, diabetes is not consistently a significant contributor in predicting short and long-term mortality.6, 7 Animal models point to number of mechanisms whereby diabetes, independent of CAD risk factors, can contribute to the development of HF such as impaired calcium handling, increased myocardial fibrosis, increased renin–angiotensin–aldosterone activation, endothelial dysfunction, mitochondrial dysfunction, and increased advanced-glycosylated end product deposition (Figure 1).5 In addition, the relationship between diabetes, IFG, and HF may not be unidirectional. The pathogenesis of both diabetes and HF appears to be strongly influenced by inflammation with biomarker studies demonstrating that, for example, GDF-15 (a marker of inflammation and remodelling), predicts the development of both HF8 and diabetes.9 Is it possible that inflammation plays a central role in the development, pathogenesis, and propagation of HF and diabetes? Furthermore, evidence that HF may contribute to the development of diabetes also exists – this requires exploration and replication.10 Is this a true central mechanism, a chance finding, or simply a harvesting effect (i.e. the phenomenon whereby outcomes occur sooner in individuals in whom it would have happened anyway?). Work by Go et al.11 and Gotsman et al.12 attempts to address these issues (summarized in table 1). These studies corroborate previous work and reveal a high prevalence of CAD and associated risk factors, such as hypertension, peripheral vascular disease, and obesity in patients with HF. Both studies look at a broad multi-ethnic population that may be underrepresented in previous studies and confirm the association that all-cause mortality is higher in patients with diabetes than in those without diabetes. However, diabetes does not seem to alter the risk of mortality in patients with a preserved ejection fraction (HF-PEF; EF >50%) possibly suggesting that these individuals experience adverse outcomes from different causes. The question remains, do IFG and diabetes differ in their relationship to outcomes? The work by Gotsman et al.12 suggests that IFG and diabetes impart the same risk of adverse outcomes in HF. Potentially, does this imply that both diabetes or IFG contribute to, or are influenced, by structural, metabolic, or inflammatory dysregulation, which also associates with the development of HF (Figure 1)? Patients with EF <50% and diabetes have a higher mortality risk compared with non-diabetics Patients with HF-PEF with or without diabetes have a similar mortality risk of mortality Patients with diabetes with only mild to moderate LVEF impairment (EF 49–30%) have equivalent mortality risk compared with non-diabetes patients with severe LV impairments (EF <30%) Patients with diabetes have a higher all-cause mortality risk and cardiac-related complications Patients with IFG have mortality risk as high as patients with diabetes Patients in the lowest strata of IFG also have poor outcomes While Go et al.,11 Gotsman et al.,12 and others1 suggest poor outcomes in the setting of diabetes and HF, it is unclear what the major driver of mortality is. Potential confounders of the mechanism of death exist, as diabetics have multiple

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.179

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 22

Metadata

Authors
Sharma, A., & Ezekowitz, J. A.
Venue
European Journal of Heart Failure
Published
2014-10-15
Volume
16
Issue
11
Pages
1153-1156
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W1573414423
Cited by
22
References
2
FWCI
1.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.